Anticoccidial Drugs

Global Anticoccidial Drugs Market to Reach US$254.6 Million by 2030

The global market for Anticoccidial Drugs estimated at US$203.1 Million in the year 2024, is expected to reach US$254.6 Million by 2030, growing at a CAGR of 3.8% over the analysis period 2024-2030. Synthetic Drugs, one of the segments analyzed in the report, is expected to record a 4.5% CAGR and reach US$148.1 Million by the end of the analysis period. Growth in the Ionophore Drugs segment is estimated at 2.9% CAGR over the analysis period.

The U.S. Market is Estimated at US$53.4 Million While China is Forecast to Grow at 3.8% CAGR

The Anticoccidial Drugs market in the U.S. is estimated at US$53.4 Million in the year 2024. China, the world`s second largest economy, is forecast to reach a projected market size of US$41.1 Million by the year 2030 trailing a CAGR of 3.8% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 3.6% and 3.3% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 3.1% CAGR.

Global Anticoccidial Drugs Market – Key Trends & Drivers Summarized

What is Fueling the Demand for Anticoccidial Drugs Worldwide?

Coccidiosis remains a persistent threat to livestock, particularly in poultry and cattle, causing significant economic losses due to morbidity, mortality, and decreased productivity. The growing global demand for protein-rich foods, such as chicken and eggs, has heightened the need for effective anticoccidial drugs. Large-scale poultry farming operations rely heavily on prophylactic and therapeutic anticoccidials to maintain herd health and prevent outbreaks. Additionally, with emerging strains of Eimeria parasites displaying resistance to traditional treatments, there is an increasing focus on developing new-generation drugs with enhanced efficacy and reduced resistance profiles. The market is also experiencing a shift towards combination therapies that integrate ionophores and synthetic anticoccidials to optimize parasite control while minimizing drug resistance.

How is Regulatory Pressure Reshaping the Anticoccidial Market?

Stringent regulations governing the use of antibiotics and medicated feed additives in animal husbandry have significantly influenced the dynamics of the anticoccidial drugs market. Governments and regulatory agencies, including the FDA and the European Medicines Agency (EMA), are enforcing strict guidelines on the use of anticoccidials to mitigate antimicrobial resistance (AMR) risks. This has led to the phasing out of certain traditional drugs, compelling pharmaceutical companies to develop alternative, non-antibiotic coccidiosis control solutions. Consequently, the industry is witnessing an increased adoption of vaccines and phytogenic feed additives, alongside a rising demand for novel anticoccidial formulations that align with regulatory compliance while ensuring sustainable livestock production.

What Role Does Technological Innovation Play in Market Evolution?

The anticoccidial drugs market is undergoing a technological transformation with advancements in drug formulation, delivery mechanisms, and precision livestock farming. New drug molecules with improved pharmacokinetics and targeted action are being developed to enhance treatment outcomes while reducing toxicity risks. Nanotechnology is also gaining traction, enabling better drug absorption and sustained release for prolonged efficacy. Additionally, the integration of artificial intelligence (AI) and big data analytics in disease surveillance is empowering farmers with real-time insights to implement timely and effective coccidiosis management strategies. These innovations are not only optimizing drug efficacy but also contributing to cost-effective and environmentally sustainable livestock rearing practices.

What Are the Key Growth Drivers Accelerating the Market Expansion? The growth in the global anticoccidial drugs market is driven by several factors, including the rising demand for high-quality animal protein, increasing livestock production, and the expansion of commercial poultry farms. Rapid urbanization and evolving dietary preferences, particularly in emerging economies, are further amplifying the need for effective disease control measures in livestock. Additionally, advancements in veterinary pharmaceuticals and the introduction of novel drug formulations are expanding the treatment landscape. The shift towards integrated coccidiosis management, incorporating vaccination, biosecurity, and novel feed additives, is also fueling market growth. Furthermore, strategic collaborations between pharmaceutical companies and research institutions to develop next-generation anticoccidials are poised to drive sustained industry expansion in the coming years.

SCOPE OF STUDY:

The report analyzes the Anticoccidial Drugs market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:
Drug Class (Synthetic Drugs, Ionophore Drugs); Drug Action (Coccidiostatic Action, Coccidiocidal Action); Animal Type (Companion Animals, Livestock Animals);

Geographic Regions/Countries:
World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; and Rest of Europe); Asia-Pacific; Rest of World.

Select Competitors (Total 36 Featured) -

• Biochem Pharmaceuticals
• Boehringer Ingelheim Animal Health USA Inc.
• Ceva Sante Animale
• Elanco Animal Health Incorporated
• HIPRA SA
• Huvepharma
• Impextraco NV
• Merck & Co., Inc. - MSD Animal Health
• Phibro Animal Health Corporation
• Vetoquinol India Animal Health Pvt Ltd
• VIRBAC Animal Health India Private Ltd.
• Zoetis India Ltd

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by artificially increasing the COGS, reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

We are diligently following expert opinions of leading Chief Economists (14,949), Think Tanks (62), Trade & Industry bodies (171) worldwide, as they assess impact and address new market realities for their ecosystems. Experts and economists from every major country are tracked for their opinions on tariffs and how they will impact their countries.

We expect this chaos to play out over the next 2-3 months and a new world order is established with more clarity. We are tracking these developments on a real time basis.

As we release this report, U.S. Trade Representatives are pushing their counterparts in 183 countries for an early closure to bilateral tariff negotiations. Most of the major trading partners also have initiated trade agreements with other key trading nations, outside of those in the works with the United States. We are tracking such secondary fallouts as supply chains shift.

To our valued clients, we say, we have your back. We will present a simplified market reassessment by incorporating these changes!

APRIL 2025: NEGOTIATION PHASE

Our April release addresses the impact of tariffs on the overall global market and presents market adjustments by geography. Our trajectories are based on historic data and evolving market impacting factors.

JULY 2025 FINAL TARIFF RESET

Complimentary Update: Our clients will also receive a complimentary update in July after a final reset is announced between nations. The final updated version incorporates clearly defined Tariff Impact Analyses.

Reciprocal and Bilateral Trade & Tariff Impact Analyses:

USA
CHINA
MEXICO
CANADA
EU
JAPAN
INDIA
176 OTHER COUNTRIES.

Leading Economists - Our knowledge base tracks 14,949 economists including a select group of most influential Chief Economists of nations, think tanks, trade and industry bodies, big enterprises, and domain experts who are sharing views on the fallout of this unprecedented paradigm shift in the global econometric landscape. Most of our 16,491+ reports have incorporated this two-stage release schedule based on milestones.

Please note: Reports are sold as single-site single-user licenses. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks. The Publisher uses digital controls protecting against copying and printing is restricted to one full copy to be used at the same location.

The latest version of Adobe Acrobat Reader is required to view the report. Upon ordering an electronic version, the Publisher will provide a link to download the purchased report.

Prior to fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher.